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Abstract
Background: Many high burden countries are scaling-up GeneXpert® MTB/RIF (Xpert) testing for tuberculosis (TB)
using a hub-and-spoke model. However, the effect of scale up on reducing TB has been limited. We sought to
characterize variation in implementation of referral-based Xpert TB testing across Uganda, and to identify health
system factors that may enhance or prevent high-quality implementation of Xpert testing services.
Methods: We conducted a cross-sectional study triangulating quantitative and qualitative data sources at 23
community health centers linked to one of 15 Xpert testing sites between November 2016 and May 2017 to assess
health systems infrastructure for hub-and-spoke Xpert testing. Data sources included a standardized site assessment
survey, routine TB notification data, and field notes from site visits.
Results: Challenges with Xpert implementation occurred at every step of the diagnostic evaluation process, leading
to low overall uptake of testing. Of 2192 patients eligible for TB testing, only 574 (26%) who initiated testing were
referred for Xpert testing. Of those, 54 (9.4%) were Xpert confirmed positive just under half initiated treatment
within 14 days (n = 25, 46%). Gaps in required infrastructure at 23 community health centers to support the hub-
and-spoke system included lack of refrigeration (n = 14, 61%) for sputum testing and lack of telephone/mobile
communication (n = 21, 91%). Motorcycle riders responsible for transporting sputum to Xpert sites operated variable
with trips once, twice, or three times a week at 10 (43%), nine (39%) and four (17%) health centers, respectively.
Staff recorded Xpert results in the TB laboratory register at only one health center and called patients with positive
results at only two health centers. Of the 15 Xpert testing sites, five (33%) had at least one non-functioning module.
The median number of tests per day was 3.57 (IQR 2.06–4.54), and 10 (67%) sites had error/invalid rates > 5%.
Conclusions: Although Xpert devices are now widely distributed throughout Uganda, health system factors across
the continuum from test referral to results reporting and treatment initiation preclude effective implementation of
Xpert testing for patients presenting to peripheral health centers. Support for scale up of innovative technologies
should include support for communication, coordination and health systems integration.
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Background
The global tuberculosis (TB) epidemic continues with an es-
timated 10.0 million cases in 2017, of which an estimated 3.7
million “missing” cases were either undiagnosed or unre-
ported to public health authorities [1]. To improve the diag-
nostic cascade of care for patients, there has been significant
global and country level investment in rapid and more sensi-
tive diagnostic tests such as GeneXpert MTB/RIF® (Xpert)
(Cepheid, Sunnyvale, USA). Since the World Health
Organization (WHO) endorsed Xpert in 2010, there has
been massive scale-up of Xpert worldwide. As of 2016, 6659
Xpert instruments (containing approximately 30,000 testing
modules) and over 23 million cartridges have been procured
through concessional pricing available to low-income coun-
tries in order to reduce the burden [2].
Because of the substantial cost and infrastructure re-
quirements of 4-module Xpert deployment, many high
burden countries have adopted a “hub-and-spoke” model
for scale-up. In this model, four module Xpert devices
are placed at higher-level health facilities with adequate
infrastructure requirements including security, stable
power supply (hubs), each of which receive sputum sam-
ples from several lower level health facilities (spokes).
The goal of these hub-and-spoke units is to expand
coverage of Xpert testing services using existing devices
and infrastructure, thereby increasing access to rapid
and more sensitive diagnostic testing for patients who
present to lower level health facilities.
Although Xpert is undoubtedly a pivotal innovation for
TB diagnostics in high burden settings [3], the impact of
Xpert scale-up on improvement of TB outcomes has been
negligible. A recent systematic review and meta-analysis of
Xpert use in programmatic settings demonstrated no bene-
fit in morbidity or mortality for individual patients [4].
Many health systems issues have been hypothesized to ex-
plain this lack of effect: from poor infrastructure to limited
quality systems for maintaining Xpert devices; to lack of
funding and use of empiric treatment. However, to date no
studies have assessed health system barriers to Xpert imple-
mentation at the facility level [5]. We sought to characterize
variation in implementation of referral-based Xpert TB
testing across Uganda, and to identify health system factors
that may reduce or enhance efficient implementation of
Xpert testing services.
Methods
Study setting and context
Uganda first adopted the use of Xpert for TB diagnosis in
patients living with HIV or requiring testing for possible
multidrug-resistant (MDR) TB in 2011. In September
2017, Uganda adopted policy recommendations in line
with WHO guidelines that recommends Xpert testing
where available for all patients with possible TB [6]. With
support from partners, Uganda has installed 249 Xpert
devices in 227 of 1500 (15%) TB diagnostic units in the
country [6]. To date, Xpert devices have been deployed at
all regional or district hospitals, most of which are serving
as testing hubs. Local motorcycle (i.e., boda) riders have
been employed by Central Public Health Laboratories
(CPHL) with support from implementing partners to carry
sputum specimens from community health centers to
Xpert testing hubs and to return to the community health
centers with results. With the establishment of this hub
and spoke network, the Ministry of Health intended that
all patients with signs or symptoms of TB presenting to
community health facilities with TB diagnostic units
would have access to rapid, referral-based Xpert testing
services. Each hub serves approximately 20–40 commu-
nity health centers, and each rider’s daily route is expected
to cover 4–8 facilities (NTRL, personal communication).
Community health centers were included in the study
if they: 1) used sputum smear microscopy as the primary
method for TB diagnosis; 2) participated in external
quality assurance testing for sputum smear microscopy
led by the National Tuberculosis and Leprosy Program
(NTLP); and 3) were linked to an Xpert testing site/hub.
Community health centers were excluded if they: 1) per-
formed sputum smear examination on < 150 patients per
year based on 2015 NTLP data; 2) diagnosed < 15
smear-positive TB cases per year; or 3) were located
within Kampala District or > 150 km from central
Kampala City. Of 1105 level III-IV community health fa-
cilities in Uganda that reported to the NTLP, 27 met eli-
gibility criteria based on review of 2015 NTLP TB
testing and treatment data. Of those eligible sites, 23
were selected for the study after consultation with the
NTLP. TB testing and treatment algorithms guidelines
of the NTLP and NTRL governed the use of smear mi-
croscopy and Xpert at participating health centers. At
the time of this study, Uganda national guidelines called
for Xpert testing in persons living with HIV, health care
workers, contacts of drug-resistant (DR-TB) patients,
pregnant women or breast-feeding mothers, prisoners,
patients from refugee camps, and diabetics.
Study design
This cross-sectional study combines several sources of tri-
angulated quantitative and qualitative data to assess the
coverage, penetration, and fidelity to implementation of
Xpert testing in Uganda’s hub and spoke model from the
perspective of level III-IV community health facilities.
Data collection
Data for this study was obtained in three ways: surveys,
data abstraction from routine health registers, and field
notes recorded by study staff from observing community
health center staff, work processes and personal commu-
nication. This data was collected as part of a mapping
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exercise in preparation for studies conducted by the
Uganda Tuberculosis Implementation Research Consor-
tium (U-TIRC) aiming to assess and improve TB diag-
nostic evaluation in Uganda.
First, to assess characteristics of the community health
centers, a research staff member administered a site assess-
ment survey to clinic staff using a standardized tool (Supple-
ment file) developed for this study to capture information on
infection control procedures; laboratory procedures; TB test-
ing and treatment procedures; and utilities, infrastructure
and resources. Survey participants included (in order of pri-
ority based on seniority, in keeping with norms in Uganda)
any of the following individuals available at the time of the
study staff site visit: the health center director (also known as
the facility in-charge), laboratory director, and/or TB focal
person at each health center.
Second, to obtain patient-level data on utilization and
outcomes of Xpert testing, we reviewed routine TB reg-
isters including NTLP laboratory registers, Xpert referral
forms, an electronic reporting platform for GeneXpert
results (GxAlert, SystemOne Northampton USA) and
NTLP treatment registers, all for the period January –
December 2016. We included data on all patients under-
going TB testing who had indications for Xpert testing
per Uganda NTLP guidelines at the time the survey was
completed. To ensure that we captured Xpert testing re-
sults, we also downloaded testing data directly from the
Xpert devices at testing hubs serving each participating
community health facility. We developed a standardized
data extraction tool to match patients across data
sources. Data abstracted included age, sex, date of initial
sputum collection, method of sputum examination
(smear microscopy, Xpert), sputum examination results,
date of results, date of treatment initiation, and HIV sta-
tus. All the data abstraction, collection, and entry was
done by trained research assistants using secure mobile-
based Research Electronic Data Capture (REDCap,
Nashville USA) [7] platform hosted by the University of
California San Francisco. To ensure data quality, data
was subjected to a rigorous quality assurance process
using REDCap generated reports on a bi-monthly basis
by our data management team.
Finally, qualitative data was collected from field notes
taken by study staff during site visits. Staff recorded obser-
vations about the TB diagnostic evaluation process in par-
ticipating community health centers during site visits for
trainings, surveys, and data abstraction. Staff were asked to
take notes related to the process of specimen collection,
specimen transport, specimen testing, result reporting and
patient linkage to treatment initiation if diagnosed with TB.
Data analysis
We compared differences in proportions across sites
using the χ2 test of proportions. Qualitative data from
field notes were organized by health center, transcribed
and reviewed for thematic interpretation using a frame-
work analysis to identify key issues related to the hub-
and-spoke model of TB diagnostic evaluation. We used
qualitative inquiry to elucidate site specific and general
health system barriers to Xpert testing. While formal
coding was not conducted, data were summarized into
categories corresponding to processes of care for TB
diagnosis (Fig. 1). We performed all quantitative analyses
using Stata version 14 (Stata Corporation, College Sta-
tion, TX). Qualitative data was categorized by theme and
reviewed in Excel (Microsoft, Redmond, WA).
The study was approved by the School of Medicine
Research and Ethics Committee at Makerere University,
the Uganda National Council for Science and Technol-
ogy, and the University of California San Francisco
Committee on Human Research.
Results
Site assessment survey
Health center characteristics
Of the 23 participating community health centers, 6 (26%)
were in the Eastern Region of Uganda and 17 (74%) in the
Central Region. Health centers were classified as Level IV
(n = 15, 65%) or Level III (n = 8, 35%), and all provided
on-site sputum smear microscopy services. Enrolled
health centers were often located in rural (n = 14, 61%)
areas and at a distance of approximately 21.5 km (km)
(IQR 13–34.5) from the closest Xpert testing hub.
Physical infrastructure, availability of water and sanitation
facilities, and availability and consistency of electricity var-
ied across the health centers (Table 1). Twenty-one sites
(91%) had consistent electricity and 22 (92%) had function-
ing water and sanitation systems, however only 13 (57%) re-
ported having refrigerators in their laboratories. Of the 14
rural health centers, a notable proportion harvested rain
water as their primary water source (n = 5, 36%) and relied
on solar panels for electricity (n = 6, 43%), although only
critical departments such as the operating theatre and the
laboratory were connected to solar power. Communication
infrastructure and capability was also limited in a majority
or health centers. Of the 23 community health centers, only
2 (9%) had access to and sufficient airtime to use mobile
phones to communicate with testing facilities or patients.
Health center staffing
In accordance with Ministry of Health staffing require-
ments, Level III health centers were led by a senior clin-
ical officer holding a diploma in clinical medicine, who
ran the general outpatient department (OPD), whereas
the Level IV health centers were led by a senior medical
officer holding a degree in medicine. In addition, only
Level IV health centers had a designated TB focal person
responsible for managing the TB unit and TB treatment
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Fig. 1 Health systems challenges to GeneXpert implementation during the TB diagnostic evaluation cascade of care. Challenges to TB diagnostic
evaluation at community health centers synthesized from both quantitative and qualitative data are mapped to specific steps in the diagnostic
evaluation process
Table 1 Characteristics of participating community health centers and Xpert hubs based on health center survey and field notes
Health Center Characteristics Proportion or Median (IQR)
(N = 23)
HC IV 65% (15)
Rural 61% (14)
Distance to nearest Xpert testing facility (km) 20.3 (13–34.5)
Have consistent electricity 91% (21)
Refrigerator 57% (13)
Have functioning water/sanitation system 92% (22)
Number of health workers 20 (15.5–25)
Transportation (weekly) 43% (10)
Notification of positive results to patients (phone call) 13%(2)
Number of Xpert tests done 13.5 (11–20)
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register, and a laboratory technologist responsible for
supervising laboratory technicians. At both Level III and
IV health centers, staff rotated daily with some assigned
to work at least 2–3 days per week and others working
full time from 9 am to 5 pm.
Chart abstraction
GeneXpert utilization
During the study period, of the 2747 adults with presumed
TB, 2192 (79.8, 95% CI 78.2–81.3%) were referred for TB
testing. Of the 1597 (72.9 95% CI 70.9–74.7%) patients
who were eligible for Xpert testing based on NTLP guide-
lines, only 574 (35.9, 95% CI 33.6–38.4%) had sputum re-
ferred for Xpert testing. Patients referred for Xpert testing
included 76 smear-negative patients (13.2 95% CI 10.6–
16.3%) and 481 persons living with HIV regardless of
smear status (83.8 95% CI 80.5–86.7%). Xpert was re-
quested as the first line test for only 39 of 2192 (1.8, 95%
CI 1.3–2.4%) patients. Of the 54 patients confirmed to
have TB by Xpert testing, 33 (61.1, 95% CI 46.9–74.1%)
were initiated on TB treatment overall and 25 (46.3, 95%
CI 32.6–60.4%) within 14 days. Median time to treatment
was longer for patients confirmed to have TB by Xpert
testing (2 days, IQR 0–14) than for those confirmed by
smear microscopy (0 days, IQR 0–1). The cumulative pro-
portion of patients diagnosed with TB who started on
treatment was lower for patients confirmed to have TB by
Xpert testing than for those confirmed by smear micros-
copy at both 7 days (38.9, 95% CI 25.9–53.1% vs. 80.5, 95%
CI 73.7–86.2%, p < 0.001) and 14 days (46.3, 95% CI 32.6–
60.4%, vs. 95, 95% CI 80.3–91.2%), p < 0. 001). Only one
patient was identified as having rifampin (RIF) resistant
TB. Even when patients obtained Xpert testing, 15% of the
Xpert testing hubs experienced at least one non-
functional module with error/invalid rates greater than 5%
at 10 (67%) testing hubs.
Field notes
Specimen collection
Sputum samples that were collected to be sent for Xpert
testing were packaged in specialized sputum mugs with a
tight lid to avoid leakage. Of 23 sites, 8 (35%) experienced
shortages of these sputum mugs, and 10 (43%) lacked electri-
city to enable refrigerated storage of samples until they were
transported for testing (Fig. 1). Sites that lacked refrigeration
equipment noted that patients who were asked to return for
sputum collection on scheduled sputum transport days fre-
quently failed to come even when asked to do so.
Specimen transport
Sputum samples collected from patients were transported
to Xpert testing hubs 1–3 times a week, with many of the
health centers (n = 10, 43%) transporting specimens at least
once a week (Fig. 1). All health centers used a boda rider to
transport sputum samples to Xpert referral sites, with each
boda rider allocated 4–8 health centers per day. Delays of
greater than 3 days in transporting sputum samples were
noted at 5/23 (22%) health centers.
Specimen testing
At the Xpert testing hubs, the numbers of samples received
are recorded in the Xpert site laboratory register as they are
tested. A lack of electricity prevented testing from being per-
formed on at least 13% of the working days year at Xpert
testing hubs because of lack of electricity (Fig. 1). Standard
recommended daily maintenance was not performed at 7/15
(47%) testing sites on any day of the year. Ten of 15 (66%)
Xpert testing sites recorded error/invalid rates > 5%, which
exceeds quality control limits. Finally, all Xpert testing sites
reported unreliable logistics for the ordering and delivery of
Xpert cartridges to maintain local site inventories.
Results receipt and notification
Positive Xpert results were variably communicated back to
health centers (Fig. 1). Some Xpert sites communicated
through a phone call or text message (SMS) to referring
health centers, while other hub-and spoke dyads relied on
when boda rider’s return to the referring health center to
disseminate test results. Results for patients referred from
each health center were printed from the Xpert machine
when the corresponding boda rider came to the Xpert site
in order to verify that the specific results provided matched
the identifiers for all of the samples that were delivered.
After confirmation, the boda rider returned the results to
the facilities on the next scheduled sputum pick-up day. A
majority of the sites experienced delays in notification of
Xpert results of up to 2 weeks after the initial request. In
some cases, results were returned only after patients had
returned for them at the sites. At the health centers, staff
inconsistently recorded Xpert results in the TB laboratory
register. Study staff noted that when asked, a majority of
health center staff including TB focal persons were not able
to identify or characterize critical process metrics for TB
care in their clinic (Fig. 1). TB focal persons at each com-
munity health center attempted to contact patients who
provided a phone number, asking them to return to the
health center to receive their Xpert test results and initiate
treatment as appropriate. Patients who did not have a tele-
phone number recorded could not be contacted and the fa-
cility had to wait until such a patient returned to the health
center to initiate treatment. The cumulative delays in
reporting and recording Xpert test results were acknowl-
edged to cause delayed treatment initiation for patients
who were microbiologically confirmed to have TB (Fig. 1).
Discussion
Our study confirms that Xpert utilization was poor
among community health centers in Uganda linked to
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Xpert testing hubs. Only 35.9% (95% CI 33.6–38.4%) of
patients eligible for TB testing were referred for Xpert
testing and only 1.8, 95% CI 1.3–2.4%) of patients with
presumed TB received Xpert as a first line test. This is
despite national policy guidelines which recommend
universal testing with Xpert when linkage to Xpert test-
ing is available, and specifically for people living with
HIV. Even when patients with presumed TB underwent
Xpert testing the median time to treatment initiation
was longer than for those who were diagnosed with
smear microscopy (median 2 days IQR 0–14 for Xpert
compared to median 0 IQR 0,1 for smear microscopy).
This result suggests that current systems for patient
linkage to Xpert have failed to improve the efficiency of
TB testing. Together these data suggest that current
methods for decentralizing Xpert testing using a hub-
and spoke model for decentralization fail to increase
both uptake of Xpert testing and improvements in
process metrics such as time to treatment initiation for
TB patients, thereby contributing to the low impact of
Xpert in high-burden settings.
Our findings are in line with other data from Uganda
reporting overall low utilization rates for Xpert testing,
with only about 20% of eligible patients at community
health centers receiving Xpert, and less than 2% being
referred for Xpert testing as a first-line test [8, 9]. A
study in Malawi evaluating the impact of Xpert roll-out
on TB diagnosis and treatment showed only a small con-
tribution to case detection. This low diagnostic impact
was attributed to operational challenges and other gaps
in the continuum of care such as difficulty in sputum
transportation and slow turnaround time in high volume
settings [10]. Results from our surveys of community
health centers and from field notes reveal additional detail
regarding operational challenges and gaps in the TB diag-
nostic cascade of care that impact Xpert effectiveness.
These included challenges at community health centers
that prevent collection and transport of sputum (stock-
outs of sputum collection supplies). Limitations with spu-
tum transportation were documented, due to an overex-
tended motorcycle rider network with ad hoc back-up
systems. Xpert testing sites, had non-functioning modules
for extended periods of time and high error/invalid rates,
making testing ineffective. Finally, communication of re-
sults to health centers and patients was limited (91% of
health centers could not relay positive Xpert results be-
cause of a lack of a mobile phone airtime). When taken in
aggregate, our study documented serious systems issues
that negatively impact the entire process of referral-based
Xpert testing. In addition, the variability of system per-
formance, capacity and efficiency at these health centers
suggest that more central coordination is required to sup-
port decentralized Xpert testing platforms.
Our results reflect detailed data collection from health
centers in 15 districts of Uganda spanning all 4 adminis-
trative regions of the country. This sampling strategy sug-
gests that our results may be generalized to rural and peri-
urban TB care across the country. Our ability to identify
challenges at each level in the Xpert referral implementa-
tion process aligns with the patient cascade of TB diagnos-
tic care in Uganda [11], which demonstrates significant of
pre-treatment loss to follow-up within this context. Our
approach in understanding operational challenges to
Xpert hub-and-spoke implementation may inform the de-
velopment of targeted strategies to address these chal-
lenges while improving patient outcomes.
Although our results reflect detailed data collection
from health centers in 15 districts of Uganda spanning all
4 administrative regions of the country, our study had
some limitations. We were unable to collect data on gaps
in health center resources and supply systems as health
center staff were unable to document or characterize sup-
ply chain operations and resource availability. Health
workers in some instances were unable to describe or
document standardized operating procedures for the
process of referring samples for Xpert testing and report-
ing results. However, these data lapses reinforce our re-
sults suggesting the limited capacity of facility staff and
providers to facilitate high-quality Xpert testing services.
Additionally, while we obtained perspectives from front-
line staff regarding gaps to provision of Xpert testing lo-
cally, we did not obtain additional perspectives from
NTRL staff nor did we attempt to conduct a quantitative
analysis of operational gaps at the national level.
Our results suggest the need for re-conceptualizing
what is meant by TB diagnostic “capacity” at the health
system level beyond simply increasing numbers of com-
modities, such as Xpert devices. A more horizontal
health systems approach to support integration, sustain-
ability, and reach of this technology is required to im-
prove implementation of Xpert and enhance its potential
effect on TB prevention and care. Funders who have
been supporting scale up of Xpert as well as other tech-
nologies to improve TB prevention and care should con-
sider supporting systems that optimize the functionality
of Xpert devices and not only focusing on procurement.
Monitoring and evaluation of Xpert implementation
could be improved by adding monitoring of facility re-
sources, infrastructure, and personnel capacity to carry
out Xpert testing, including coordination or referral and
reporting in addition to device specific quality assurance
[12]. Our results suggest that integration and sustainabil-
ity of Xpert testing across the health system, could be
improved with better improved and standardized sys-
tems bi-directional communication and linkage between
testing facilities and referring health centers, on-going
training and support for providers to maintain networks,
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and programmatic provisions to support the mainten-
ance and use of Xpert technology. Strategies that incorp-
orate novel laboratory services within existing health
and laboratory service delivery schemes have the benefit
of strengthening health systems while achieving disease
specific goals [13].
Conclusions
This study highlights the need for a more holistic health
systems approach to the deployment and integration of
technologies such as GeneXpert in routine health set-
tings. Additional operational, implementation, and ap-
plied health systems research to design robust these
strategies is a first step in maximizing the public health
impact of these of novel interventions.
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